ReviewMaternal-fetal medicine (Wolters Kluwer Health, Inc.)2026
Long-Term Maternal and Offspring Adverse Effects of Gestational Diabetes Mellitus.
Review in Maternal-fetal medicine (Wolters Kluwer Health, Inc.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Maternal and Offspring Adverse Effects of Gestational Diabetes Mellitus.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational diabetes mellitus (GDM) serves as a diagnostic "stress test" for maternal physiology, exposing underlying metabolic vulnerabilities that imply a potential lifelong cardiometabolic trajectory for both mother and offspring. Mothers with a history of GDM face a 6-to-10-fold increased risk of developing type 2 diabetes mellitus and a 1.4-to-2.0-fold higher risk of cardiovascular disease, chronic hypertension, and chronic kidney disease. These risks are further compounded by factors such as obesity, hypertension, or adverse postpartum weight gain. For offspring, in utero exposure to hyperglycemia is thought to contribute to developmental programming that increases obesity risk-rising from approximately 1.1-fold in early childhood to 2.0-fold by adolescence-and predisposes them to early-onset dysglycemia. Although modest associations between in utero GDM exposure and both neurodevelopmental disorders and early cardiovascular events have been documented, these outcomes appear highly dependent on the postnatal environment. Despite the heterogeneity in findings among observational studies and variations in GDM diagnostic criteria, GDM should be regarded as a critical marker of long-term intergenerational risk for these adverse cardiometabolic and developmental outcomes. This review advocates for a clinical paradigm shift, positioning GDM as a sentinel event that requires a transition from episodic pregnancy care toward sustained, life-course cardiometabolic surveillance and preventative strategies for both mother and offspring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.